Assessing Functional Quality of Single TILs for Correlative Immunotherapy Biomarkers

Learn how using Single-Cell PSI™ can help you reveal mechanism in the Tumor Microenvironment.

Unlock Resource
Download this free resource and gain access to our full resource library!

Unlock All Resources

We will always keep your personal information safe. Complete this form to get unlimited access to all of our web resources and join over 10,000 leading researchers who receive industry pioneers' backed data straight to their inbox. By submitting this form, you agree to receive communications from IsoPlexis and accept our Privacy Policy.

You may unsubscribe and update your email subscription at any time.

fierce innovation award
red dot award winner
scientist award

Challenge: Checkpoint combination studies need TILs solutions

Recently, checkpoint inhibitor blockade therapy has rapidly advanced and is now established as a powerful way to manage various malignant tumors. Despite the promising outcomes, there are a significant number of patients who do not respond to these immunotherapies.

In this Application Note we discuss:
  • Highlight the challenges in functional characterization of TILs in checkpoint and combination therapies
  • Describe the workflow for functional single-cell analysis from both solid tumor TILs as well as patient PBMC
  • Predict patient response to checkpoint therapy using PSI as a biomarker in solid tumor TILs, as well as correlate response from these solid tumor TILs with PSI from peripheral blood
2019-11-16T11:59:38-05:00